Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
furaprevir + yimitasvir + ribavirin
- Development stage
- Unknown
- Lead developer
- HEC TaiGen Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
furaprevir + yimitasvir + ribavirin is a combination antiviral therapy developed by Dongguan Dongyangguang Taijing Pharmaceutical (HEC Pharm) for the treatment of chronic hepatitis C virus (HCV) infection. The regimen consists of three active components: furaprevir, a second-generation NS3/4A protease inhibitor; yimitasvir, a potent NS5A inhibitor; and ribavirin, a guanosine analog that acts as a broad-spectrum antiviral. This triple therapy is designed to achieve high sustained virologic response (SVR) rates by targeting multiple stages of the HCV life cycle, thereby increasing the genetic barrier to resistance. It has been primarily evaluated in clinical trials within China, focusing on patients with various HCV genotypes, including those with compensated cirrhosis.
- Other names
- furaprevir/yimitasvir/ribavirinHEC11011 + HEC74647 + ribavirin
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on furaprevir + yimitasvir + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on furaprevir + yimitasvir + ribavirin.